RU94045155A - Способы ингибирования болезни альцгеймера - Google Patents
Способы ингибирования болезни альцгеймераInfo
- Publication number
- RU94045155A RU94045155A RU94045155/14A RU94045155A RU94045155A RU 94045155 A RU94045155 A RU 94045155A RU 94045155/14 A RU94045155/14 A RU 94045155/14A RU 94045155 A RU94045155 A RU 94045155A RU 94045155 A RU94045155 A RU 94045155A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- formula
- treatment
- methods
- alzheimer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Abstract
Данное изобретение включает способы ингибирования болезни Альцгеймера, состоящие во введении человеку при необходимости лечения эффективного количества соединения формулы I, приведенной в описании.Данное изобретение предлагает также способы увеличения выделения в головной мозг TGF-бета, включающие введение человеку при необходимости лечения эффективного количества соединения формулы 1. Данное изобретение предлагает также способы ингибирования нейротоксичности, проводимой бета-амилоидными пептидами, или воспалительной реакции, связанной с болезнью Альцгеймера (БА), включающие введение человеку при необходимости лечения эффективного количества соединения формулы 1
Claims (1)
- Данное изобретение включает способы ингибирования болезни Альцгеймера, состоящие во введении человеку при необходимости лечения эффективного количества соединения формулы I, приведенной в описании.Данное изобретение предлагает также способы увеличения выделения в головной мозг TGF-бета, включающие введение человеку при необходимости лечения эффективного количества соединения формулы 1. Данное изобретение предлагает также способы ингибирования нейротоксичности, проводимой бета-амилоидными пептидами, или воспалительной реакции, связанной с болезнью Альцгеймера (БА), включающие введение человеку при необходимости лечения эффективного количества соединения формулы 1.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/171,387 US5552415A (en) | 1993-12-21 | 1993-12-21 | Method of inhibiting Alzheimer's Disease |
US08/171,387 | 1993-12-21 | ||
US08/171387 | 1993-12-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU94045155A true RU94045155A (ru) | 1996-11-10 |
RU2128992C1 RU2128992C1 (ru) | 1999-04-20 |
Family
ID=22623556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU94045155A RU2128992C1 (ru) | 1993-12-21 | 1994-12-19 | Средство для ингибирования нейротоксичности, вызываемой бета-амилоидными пептидами |
Country Status (14)
Country | Link |
---|---|
US (3) | US5552415A (ru) |
EP (1) | EP0659418A1 (ru) |
JP (1) | JPH07215854A (ru) |
KR (1) | KR950016738A (ru) |
CN (2) | CN1087937C (ru) |
AU (1) | AU688815B2 (ru) |
CA (1) | CA2138495A1 (ru) |
CZ (1) | CZ288984B6 (ru) |
HU (1) | HUT71465A (ru) |
IL (1) | IL112050A (ru) |
NO (1) | NO944928L (ru) |
NZ (1) | NZ270177A (ru) |
RU (1) | RU2128992C1 (ru) |
ZA (1) | ZA9410095B (ru) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1996040098A2 (en) | 1995-06-07 | 1996-12-19 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US5554601A (en) * | 1993-11-05 | 1996-09-10 | University Of Florida | Methods for neuroprotection |
US5859001A (en) * | 1996-01-11 | 1999-01-12 | University Of Florida Research Foundation, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
US6197833B1 (en) | 1995-07-24 | 2001-03-06 | Apollo Biopharmaceutics, Inc. | Neuroprotective effects of polycyclic phenolic compounds |
US6319914B1 (en) | 1993-11-05 | 2001-11-20 | Apollo Biopharmaceuticals, Inc. | Cytoprotective effect of polycyclic phenolic compounds |
US6489355B2 (en) * | 1993-12-01 | 2002-12-03 | Eli Lilly And Company | Methods of inhibiting the effects of amyloidogenic proteins |
US6417198B1 (en) | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
US5596106A (en) * | 1994-07-15 | 1997-01-21 | Eli Lilly And Company | Cannabinoid receptor antagonists |
US5434166A (en) * | 1994-08-22 | 1995-07-18 | Eli Lilly And Company | Methods of inhibiting demyelinating and desmyelinating diseases |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US7069634B1 (en) | 1995-04-28 | 2006-07-04 | Medtronic, Inc. | Method for manufacturing a catheter |
JPH11506923A (ja) * | 1995-06-06 | 1999-06-22 | アセナ ニューロサイエンシーズ,インコーポレイテッド | 新しいカテプシンならびにその阻害のための方法および組成物 |
AU6507996A (en) * | 1995-07-24 | 1997-02-18 | University Of Florida Research Foundation, Inc. | Use of non-estrogen polycyclic phenol compounds for the manufacture of a medicament for conferring neuroprotection to cells |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120269A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease |
US7189222B2 (en) | 1996-04-30 | 2007-03-13 | Medtronic, Inc. | Therapeutic method of treatment of alzheimer's disease |
US5846220A (en) * | 1996-04-30 | 1998-12-08 | Medtronic, Inc. | Therapeutic method for treatment of Alzheimer's disease |
US6096782A (en) * | 1996-11-22 | 2000-08-01 | Athena Neurosciences, Inc. | N-(aryl/heteroaryl) amino acid derivatives pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6642261B2 (en) | 1997-11-21 | 2003-11-04 | Athena Neurosciences, Inc. | N-(aryl/heteroarylacety) amino acid esters, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6172043B1 (en) | 1997-01-10 | 2001-01-09 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides |
US6942963B1 (en) | 1997-01-10 | 2005-09-13 | Massachusetts Institute Of Technology | Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides |
ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
AU7237198A (en) * | 1997-05-21 | 1998-12-11 | Shionogi & Co., Ltd. | Remedies for dementia of alzheimer type containing gamma-sultam derivatives |
US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US6096781A (en) * | 1997-11-14 | 2000-08-01 | Eli Lilly And Company | 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome |
EP1067128A4 (en) * | 1998-04-01 | 2001-11-21 | Ono Pharmaceutical Co | CONDENSED THIOPHENE DERIVATIVES AND MEDICINES THAT CONTAIN THEM AS ACTIVE ACTIVE SUBSTANCES |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
CN1305377A (zh) * | 1998-06-16 | 2001-07-25 | 伊莱利利公司 | 提高乙酰胆碱水平的方法 |
SK18812000A3 (sk) * | 1998-06-16 | 2002-01-07 | Eli Lilly And Company | Spôsoby zvyšovania hladín acetylcholínu |
EP0976404A3 (en) * | 1998-07-30 | 2001-06-27 | Pfizer Products Inc. | A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal |
US6258826B1 (en) | 1998-10-13 | 2001-07-10 | Eli Lilly And Company | Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome |
AU777770C (en) | 1999-05-04 | 2005-11-10 | Strakan International Limited | Androgen glycosides and androgenic activity thereof |
US6326365B1 (en) | 1999-07-20 | 2001-12-04 | Apollo Biopharmaceutics, Inc. | Methods of prevention and treatment of ischemic damage |
US6339078B1 (en) | 1999-07-20 | 2002-01-15 | University Of Florida Research Foundation, Inc. | Methods of prevention and treatment of ischemic damage |
AR027878A1 (es) * | 1999-11-05 | 2003-04-16 | Wyeth Corp | Metodos para identificar y utilizar compuestos inhibidores de amiloides |
WO2002035987A2 (en) * | 2000-11-03 | 2002-05-10 | Massachusetts Institute Of Technology | METHODS FOR IDENTIFYING TREATMENTS FOR NEUROTOXICITY IN ALZHEIMER'S DISEASE CAUSED BY β-AMYLOID PEPTIDES |
US7067550B2 (en) * | 2000-11-03 | 2006-06-27 | Massachusetts Institute Of Technology | Treatments for neurotoxicity in Alzheimer's Disease |
US20070208087A1 (en) | 2001-11-02 | 2007-09-06 | Sanders Virginia J | Compounds, compositions and methods for the treatment of inflammatory diseases |
CN100422180C (zh) * | 2001-04-23 | 2008-10-01 | 宾夕法尼亚州大学理事会 | 淀粉样斑块聚集抑制剂和诊断成像剂 |
DE10163239A1 (de) * | 2001-12-21 | 2003-07-10 | Aventis Pharma Gmbh | Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament |
PT1511710E (pt) | 2002-05-31 | 2014-02-26 | Proteotech Inc | Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson |
JP3887588B2 (ja) * | 2002-08-30 | 2007-02-28 | 株式会社リガク | X線回折による応力測定法 |
WO2005105063A1 (en) * | 2004-05-03 | 2005-11-10 | Universita' Degli Studi Di Firenze | Pharmaceutical compositions containing serms for the treatment of alzheimer's disease |
US20080312587A1 (en) * | 2005-06-10 | 2008-12-18 | Gruenethal Gmbh | System for the Oral Administration of Solids to Persons Suffering from Dementia |
DE102005028862A1 (de) * | 2005-06-22 | 2007-01-11 | Sanofi-Aventis Deutschland Gmbh | Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
ES2332687B1 (es) * | 2008-03-13 | 2011-01-10 | Proyecto De Biomedicina Cima, S.L. | Nuevos usos de 4pba y sus sales farmaceuticamente aceptables. |
WO2010009327A1 (en) | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
WO2010138869A1 (en) * | 2009-05-29 | 2010-12-02 | The Trustees Of Columbia University In The City Of New York | Modulation of phospholipase d for the treatment of neurodegenerative disorders |
CN111601595A (zh) * | 2018-01-24 | 2020-08-28 | 三井制糖株式会社 | 抗i型变态反应剂、和肥大细胞或嗜碱性粒细胞的脱颗粒抑制剂、以及抗痴呆症剂、和短期记忆障碍改善/抑制剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR7461M (ru) * | 1968-06-19 | 1970-01-05 | ||
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
WO1993011074A1 (en) * | 1991-11-25 | 1993-06-10 | Healthguard, Incorporated | Multistage coaxial encapsulated filter assembly |
DE4311870C2 (de) * | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
IL109990A (en) * | 1993-06-21 | 1999-06-20 | Lilly Co Eli | Materials and methods for screening anti-osteoporosis agents |
DE4320896A1 (de) * | 1993-06-24 | 1995-01-05 | Denecke Rainer Dr Med Vet | Präparat zur Therapie und Prophylaxe von Demenz-Erkrankungen |
US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
-
1993
- 1993-12-21 US US08/171,387 patent/US5552415A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 CN CN94119268A patent/CN1087937C/zh not_active Expired - Fee Related
- 1994-12-19 JP JP6314555A patent/JPH07215854A/ja active Pending
- 1994-12-19 EP EP94309476A patent/EP0659418A1/en not_active Withdrawn
- 1994-12-19 HU HU9403668A patent/HUT71465A/hu unknown
- 1994-12-19 KR KR1019940034929A patent/KR950016738A/ko not_active Application Discontinuation
- 1994-12-19 ZA ZA9410095A patent/ZA9410095B/xx unknown
- 1994-12-19 NZ NZ270177A patent/NZ270177A/xx unknown
- 1994-12-19 CZ CZ19943220A patent/CZ288984B6/cs not_active IP Right Cessation
- 1994-12-19 NO NO944928A patent/NO944928L/no unknown
- 1994-12-19 IL IL11205094A patent/IL112050A/en not_active IP Right Cessation
- 1994-12-19 CA CA002138495A patent/CA2138495A1/en not_active Abandoned
- 1994-12-19 RU RU94045155A patent/RU2128992C1/ru active
- 1994-12-19 AU AU81546/94A patent/AU688815B2/en not_active Ceased
-
1995
- 1995-03-15 US US08/404,700 patent/US5686476A/en not_active Expired - Fee Related
-
1996
- 1996-05-09 US US08/645,013 patent/US5652259A/en not_active Expired - Fee Related
-
2000
- 2000-08-14 CN CN00124184A patent/CN1294913A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
NO944928L (no) | 1995-06-22 |
HUT71465A (en) | 1995-11-28 |
US5686476A (en) | 1997-11-11 |
CN1294913A (zh) | 2001-05-16 |
NO944928D0 (no) | 1994-12-19 |
ZA9410095B (en) | 1996-06-19 |
AU8154694A (en) | 1995-06-29 |
CN1108098A (zh) | 1995-09-13 |
CZ322094A3 (en) | 1995-09-13 |
CA2138495A1 (en) | 1995-06-22 |
IL112050A (en) | 1999-03-12 |
US5552415A (en) | 1996-09-03 |
AU688815B2 (en) | 1998-03-19 |
KR950016738A (ko) | 1995-07-20 |
JPH07215854A (ja) | 1995-08-15 |
CN1087937C (zh) | 2002-07-24 |
US5652259A (en) | 1997-07-29 |
IL112050A0 (en) | 1995-03-15 |
CZ288984B6 (cs) | 2001-10-17 |
NZ270177A (en) | 1997-08-22 |
EP0659418A1 (en) | 1995-06-28 |
HU9403668D0 (en) | 1995-02-28 |
RU2128992C1 (ru) | 1999-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
RU94036758A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома | |
ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
TW200607512A (en) | Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of migraine headaches | |
RU94044671A (ru) | Применение непептидных антагонистов рецептора тахикинина | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
AP1398A (en) | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives. | |
MXPA04005156A (es) | Antagonistas del receptor de adenosina a2a. | |
RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
DE69426334T2 (de) | Parenterales Busulfan zur Behandlung von malignen Krankheiten | |
RU94045278A (ru) | Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом | |
RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
RU94036771A (ru) | Ингибиторы ангиогенеза и ангиогенных заболеваний | |
RU94037246A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща | |
DE69819110D1 (de) | Ein Arzneimittel zur Behandlung von Fettleibigkeit und Verbesserung des lipidmetabolismus | |
RU94037233A (ru) | Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований | |
RU94045277A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования расстройств цнс у женщин в постменопаузе | |
RU94046141A (ru) | Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция | |
DE69500673D1 (de) | Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind | |
RU94045271A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера | |
CY1105545T1 (el) | Θεραπεια στατινης για ενισχυση της διατηρησης νοητικης λειτουργιας | |
RU94045156A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания | |
MY104521A (en) | Treatment of depression. | |
PT768083E (pt) | Sertralina para o tratamento de doentes pos-enfarte miocardico |